Pharsight

Loxo Oncol patents expiration

1. Jaypirca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10342780 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

US10695323 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10918622 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

US10464905 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 27, 2030
New Chemical Entity Exclusivity (NCE) Jan 27, 2028

Drugs and Companies using PIRTOBRUTINIB ingredient

NCE-1 date: 2027-01-27

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

JAYPIRCA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic